ClinicalTrials.gg
CompletedNCT05343871Updated Jan 30, 2024

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

A Phase 4 interventional study of Sinovac and AZD1222 in COVID-19, sponsored by Albert B. Sabin Vaccine Institute. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Albert B. Sabin Vaccine Institute · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,354
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies testing ChAdOx1 nCoV-19 in COVID-19 — none open to participants now, none under way, none of them phase 3. ChAdOx1 nCoV-19 · COVID-19.

Enrollment
9th of 24
2,354 · median 840
Started
2022
with 3 others
Phase 4
5 of 24
none open now
Registered
20th of 24
by date
Lead sponsor
1 of 24
Albert B. Sabin Vaccine Institute

Among the 24 studies testing ChAdOx1 nCoV-19 in COVID-19, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 4, and was the 20th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 24 studies testing ChAdOx1 nCoV-19 in COVID-19 is open now. The open studies under COVID-19, anywhere →

About ChAdOx1 nCoV-19

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing ChAdOx1 nCoV-19 in COVID-19 as a file.
02

Study summary

Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with variant-fueled case spikes causing repeated cycles of morbidity and mortality. The rapid development and emergency use authorization of vaccines against SARS-CoV-2 presents an enormous opportunity to protect populations, but bottlenecks in production have led to demand for vaccines that far outpaces supply. This project will investigate the immunogenicity of fractional doses of SARS-CoV-2 vaccines given a minimum of six months following an initial two-dose schedule or following natural immunity via documented infection. The consortium of research partners from the Sabin Vaccine Institute, Aga Khan University, Fundação Oswaldo Cruz (Fiocruz), and Stanford University will recruit volunteers to receive a full or fractional booster dose of BNT162b2, AZD1222 or Sinovac following receipt of their primary vaccination series or PCR-confirmed natural infection in Pakistan. The research team will follow participants for six months from boosting, with blood draws at baseline, 28 days, 3 months and 6 months, and measure sero-response rate (SRR) by anti-Spike immunoglobulin G (IgG) binding enzyme-linked immunosorbent assay (ELISA) with the ultimate aim of identifying whether fractional doses provide a similar immune response compared to full doses of vaccine.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Fractional dose
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female individuals aged 18 years to 60 years
  • Participant is willing and able to give written for participation in the trial
  • Individuals who can comply with trial procedures and are available for the duration of follow-up.

Brazil:

● Previous vaccination with a complete primary series of Sinovac (Priming Group 1), AZD1222 (Priming Group 2), or BNT162b2 (Priming Group 3-B) at least 6 months prior to screening

Pakistan:

● Previous vaccination with a complete primary series of Sinovac (Priming Group 1) or AZD1222 (Priming Group 2) at least 6 months prior to screening, or PCR-confirmed natural infection (Priming Group 3-P) between February 2021 - 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Has a to BNT162b2, AZD1222 or Sinovac
  • Has received an incomplete primary COVID-19 vaccination series
  • Has received 3 doses of COVID-19 vaccine
  • Has received heterologous primary COVID-19 vaccination series
  • History of a solid organ or bone marrow transplant
  • History of (other than non-melanoma skin cancer) within the past five years
  • Currently on hemodialysis
  • Any confirmed or suspected or immunodeficiency condition or diagnosis
  • On chronic (>30 days) use of immunosuppressive medications at the time of enrollment (except topical or short-term oral steroids, i.e., ≤14 days)
  • Known diagnosis of with \<200 cells/mm3 (in the past 6 months)
  • Active or history of previous auto-immune neurological disorders (e.g., multiple sclerosis, Guillain-Barre syndrome, transverse myelitis) (excluding Bell's palsy)
  • Has received anti-CD20 monoclonal antibodies for any reason in the past 12 months
  • Has received monoclonal antibodies to treat a previous COVID-19 event
  • Pregnant at screening
  • Positive SARS-CoV-2 Antigen test in respiratory specimen at screening
  • Planning to migrate out of the study area within 6 months of the enrollment
  • Participants currently enrolled in any other COVID-19 vaccine research trial in which they are getting a COVID-19 vaccine during the study period
  • Illiterate individuals (Brazil only)
  • Has a severe and/or uncontrolled comorbidity

Pakistan (natural infection Priming Group (Priming Group 3-P)):

● Prior vaccination with ANY vaccine against COVID-19

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,354 participants (actual)

Study arms

  • Experimental
    Priming Group 1: Sinovac Prime, AZD1222 ½ dose (Brazil only)

    Biological: AZD1222

  • Active comparator
    Priming Group 1: Sinovac Prime, AZD1222 full dose (Brazil only)

    Biological: AZD1222

  • Experimental
    Priming Group 1: Sinovac Prime, BNT162b2 1/3 dose

    Biological: BNT162b2

  • Experimental
    Priming Group 1: Sinovac Prime, BNT162b2 1/2 dose

    Biological: BNT162b2

  • Active comparator
    Priming Group 1: Sinovac Prime, BNT162b2 full dose

    Biological: BNT162b2

  • Active comparator
    Priming Group 1: Sinovac Prime, Sinovac full dose

    Biological: Sinovac

  • Experimental
    Priming Group 2: AZD1222 Prime, AZD1222 ½ dose (Brazil only)

    Biological: AZD1222

  • Active comparator
    Priming Group 2: AZD1222 Prime, AZD1222 full dose (Brazil only)

    Biological: AZD1222

  • Experimental
    Priming Group 2: AZD1222 Prime, BNT162b2 1/3 dose

    Biological: BNT162b2

  • Experimental
    Priming Group 2: AZD1222 Prime, BNT162b2 1/2 dose

    Biological: BNT162b2

  • Active comparator
    Priming Group 2: AZD1222 Prime, BNT162b2 full dose

    Biological: BNT162b2

  • Experimental
    Priming Group 3-B: BNT162b2 Prime, AZD1222 ½ dose (Brazil only)

    Biological: AZD1222

  • Active comparator
    Priming Group 3-B: BNT162b2 Prime, AZD1222 full dose (Brazil only)

    Biological: AZD1222

  • Experimental
    Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/3 dose (Brazil only)

    Biological: BNT162b2

  • Experimental
    Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/2 dose (Brazil only)

    Biological: BNT162b2

  • Active comparator
    Priming Group 3-B: BNT162b2 Prime, BNT162b2 full dose (Brazil only)

    Biological: BNT162b2

  • Experimental
    Priming Group 3-P: Natural Infection Prime, BNT162b2 1/3 dose (Pakistan only)

    Biological: BNT162b2

  • Experimental
    Priming Group 3-P: Natural Infection Prime, BNT162b2 1/2 dose (Pakistan only)

    Biological: BNT162b2

  • Active comparator
    Priming Group 3-P: Natural Infection Prime, BNT162b2 full dose (Pakistan only)

    Biological: BNT162b2

Interventions

  • BiologicalSinovac

    Sinovac inactivated COVID-19 vaccine: ● Full dose (0.5 ml)

  • BiologicalChAdOx1 nCoV-19Studies of ChAdOx1 nCoV-19ChAdOx1 nCoV-19 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: * Full dose (0.5 ml) * Half dose (0.25 ml)

  • BiologicalBNT162 VaccineStudies of BNT162 VaccineBNT162 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pfizer/BioNTech BNT162b2 mRNA vaccine: * Full dose (30 micrograms) * Half dose (15 micrograms) * One-third dose (10 micrograms)

06

What researchers measure

Primary outcomes

  1. Sero-response rate by Spike IgG binding ELISA at 28 days post booster

    Assess and compare humoral immune response from a fractional vs. full booster dose of BNT162b2 or AZD1222 in immunocompetent adults fully primed with BNT162b2, AZD1222, or Sinovac vaccines or natural infection, measured by anti-Spike IgG binding ELISA at 28 days post booster

    Time frame: Day 28

  2. Safety and reactogenicity profile of fractional and full dose of study vaccines at 28 days post-booster vaccination

    Describe the safety and reactogenicity profile of fractional and full dose of study vaccines at 28 days post-booster vaccination through estimated incidence of solicited local and systemic adverse events, and incidence of unsolicited reported adverse events 1. Occurrence of solicited local and systemic reactions within 7 days of booster 2. Occurrence of unsolicited AEs within 28 days of booster

    Time frame: Day 28

Secondary outcomes

  1. Sero-response rate by anti-Spike IgG binding ELISA at 3m and 6m post booster

    Assess the persistence of humoral immunity after a fractional vs. full booster dose of BNT162b2 or AZD1222 in immunocompetent adults fully primed with BNT162b2, AZD1222, or Sinovac vaccines or natural infection, measured by anti-Spike IgG binding ELISA at 3m and 6m post booster

    Time frame: Month 3 and Month 6

  2. Safety and reactogenicity profile of fractional and full dose of study vaccines throughout the trial

    Describe the safety and reactogenicity profile of fractional and full dose of study vaccines throughout the trial 1. Occurrence of Medically attended adverse reactions within 3 months of booster 2. Occurrence of adverse events (AE), Serious adverse events (SAE), and adverse events of special interest (AESI) within 28 days, 3 months, and 6 months of booster

    Time frame: Throughout study, 6 months per participant

07

Study locations

2 sites
  • FIOCRUZ
    Campo Grande, MS Do Sul, Brazil
  • Aga Khan University Clinical Trials Unit
    Karachi, Sindh, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2023, 12 months.

Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 12 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 25, 2022
StartActual
Jul 5, 2022
Primary completionActual
Jul 28, 2023
CompletionActual
Jan 11, 2024
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05343871
Lead sponsor
Albert B. Sabin Vaccine Institute
Collaborators
Aga Khan University, Oswaldo Cruz Foundation, Stanford University
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Jul 5, 2022
Primary completion
Jul 28, 2023
Completion
Jan 11, 2024
Last update
Jan 30, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ChAdOx1 nCoV-19 · BNT162 Vaccine

Start the discussion